TW200800153A - Composition for inhibiting low blood sugar syndrome - Google Patents
Composition for inhibiting low blood sugar syndrome Download PDFInfo
- Publication number
- TW200800153A TW200800153A TW095137284A TW95137284A TW200800153A TW 200800153 A TW200800153 A TW 200800153A TW 095137284 A TW095137284 A TW 095137284A TW 95137284 A TW95137284 A TW 95137284A TW 200800153 A TW200800153 A TW 200800153A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- group
- chain amino
- isoleucine
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 10
- 239000008280 blood Substances 0.000 title abstract description 31
- 210000004369 blood Anatomy 0.000 title abstract description 31
- 208000011580 syndromic disease Diseases 0.000 title abstract description 3
- 210000004958 brain cell Anatomy 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 208000024891 symptom Diseases 0.000 claims description 45
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 41
- 208000013016 Hypoglycemia Diseases 0.000 claims description 36
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 34
- 150000001720 carbohydrates Chemical class 0.000 claims description 30
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 29
- 229960000310 isoleucine Drugs 0.000 claims description 29
- 229960003136 leucine Drugs 0.000 claims description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 24
- 229930182844 L-isoleucine Natural products 0.000 claims description 23
- 239000008103 glucose Substances 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 20
- 210000004556 brain Anatomy 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000004395 L-leucine Substances 0.000 claims description 16
- 235000019454 L-leucine Nutrition 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 230000003834 intracellular effect Effects 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 8
- 229960002429 proline Drugs 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229930182821 L-proline Natural products 0.000 claims description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019204 saccharin Nutrition 0.000 claims description 6
- 229940081974 saccharin Drugs 0.000 claims description 6
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 229960003646 lysine Drugs 0.000 claims description 3
- 230000002889 sympathetic effect Effects 0.000 claims description 3
- 230000002518 glial effect Effects 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 33
- 239000002253 acid Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 239000007788 liquid Substances 0.000 description 22
- 229930003231 vitamin Natural products 0.000 description 22
- 229940088594 vitamin Drugs 0.000 description 22
- 235000013343 vitamin Nutrition 0.000 description 22
- 239000011782 vitamin Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- -1 (1)) Chemical compound 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 210000005013 brain tissue Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 8
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000000052 vinegar Substances 0.000 description 8
- 235000021419 vinegar Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 244000215068 Acacia senegal Species 0.000 description 5
- 229920000084 Gum arabic Polymers 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 5
- 239000000205 acacia gum Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Chemical class 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- XKZZNHPZEPVUQK-JEDNCBNOSA-N (2s)-2-amino-4-methylpentanoic acid;hydron;chloride Chemical compound Cl.CC(C)C[C@H](N)C(O)=O XKZZNHPZEPVUQK-JEDNCBNOSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- QKEWQOJCHPFEAF-UHFFFAOYSA-N 3,6-diaminohexanoic acid Chemical compound NCCCC(N)CC(O)=O QKEWQOJCHPFEAF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- MYGVPKMVGSXPCQ-JEDNCBNOSA-N Methylmethionine sulfonium salt Chemical compound [Cl-].C[S+](C)CC[C@H](N)C(O)=O MYGVPKMVGSXPCQ-JEDNCBNOSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- MBPFNOMGYSRGQZ-XZAHOWHSSA-N P(=O)(O)(O)OC[C@H]([C@H]([C@@H]([C@H](C(=O)[3H])[3H])O)O)O Chemical compound P(=O)(O)(O)OC[C@H]([C@H]([C@@H]([C@H](C(=O)[3H])[3H])O)O)O MBPFNOMGYSRGQZ-XZAHOWHSSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- DJMDYRLUZYGZLZ-UHFFFAOYSA-N decan-1-amine;propan-1-amine Chemical compound CCCN.CCCCCCCCCCN DJMDYRLUZYGZLZ-UHFFFAOYSA-N 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- JYCKNDWZDXGNBW-UHFFFAOYSA-N dipropyl sulfate Chemical class CCCOS(=O)(=O)OCCC JYCKNDWZDXGNBW-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- OJDNFXUNDNXMPS-UHFFFAOYSA-N guanidine;2-sulfanylacetic acid Chemical compound NC(N)=N.OC(=O)CS OJDNFXUNDNXMPS-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 235000007183 paleface Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- QJFMCHRSDOLMHA-UHFFFAOYSA-N phenylmethanamine;hydrobromide Chemical compound Br.NCC1=CC=CC=C1 QJFMCHRSDOLMHA-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- PNYYBUOBTVHFDN-UHFFFAOYSA-N sodium bismuthate Chemical compound [Na+].[O-][Bi](=O)=O PNYYBUOBTVHFDN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Jellies, Jams, And Syrups (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
200800153 九、發明說明: "【發明所屬之技術領域】 . 本發明係有關含有以支鏈胺基酸、或其藥理學上可接 受之鹽或該等之衍生物作為有效成分之低血糖症狀抑制用 組成物或腦細胞内糖質攝取之促進劑。 【先前技術】 低血糖症狀為血中之葡萄糖值減少伴隨腦内葡萄糖水 平降低’而引起之疲勞感、全身不快感、不安感、倦急感、 神、、·工過敏發抖、頭痛、脫力感、冒冷汗、心跳力口快等症 狀,更會引起意識障礙、昏睡,嚴重時會導至死亡。 引起低血糖症狀之原因主要列舉以下之情況。 (1)糖尿病患者投予過多血糖降低劑(胰島素等) (2 )某種醫藥品之副作用所引起 (3)長期持續攝取多量糖分之飲食生活 (4)過度攝取酒精 ⑩(5 )長時間持續過度運動、飲食不足之狀態 尤其以(1)或(2)之情況,因藥物強制使血糖降低,症 狀變成嚴重之可能性高,非常危險。 以往,低血糖症狀之簡單預防或治療通常為攝取葡萄 糖或砂糖或碳水化合物。惟,攝取糖質不僅對糖尿病病東 之治療有惡影響,對於健康人亦有可能造成熱量過多。 另一方面,含有本發明有效成分之支鏈胺基酸之藥 劑,已知有經口攝取支鏈胺基酸之肌肉痛、肌肉僵硬或緊 細之解除劑(簽照專利文獻丨)或經口攝取支鏈胺基酸之運 318661 5 200800153 動時瞬間或持久性肌力維持藥(參照專利文獻2)。該等係 ‘著眼於白胺酸、異白胺酸或纈胺酸等具有以肌肉為主,而 ,在腎臟等肝以外組織利用之臟器特異性之支鏈胺基酸,而 發現對改善肌肉痛或肌肉僵硬或維持運動時瞬間或持久性 肌力有效。又’已知有含有支鏈胺基酸為待徵之中樞神經 系疲勞恢復劑(參照專利文獻3)等。該等在解釋中柩神經 ,系疲勞之作用機序時,可論證支鏈胺基酸及血液腦關門上 、·之L—系統傳遞質(L-system transpoter)之特異性阻礙劑 2 胺基一環[2· 2· 1 ]庚烧-2-叛酸(2-ami nob i eye 1〇 [2· 2· 1 ]heptane-2-carboxyl ic acid)可抑制中樞神經系 之疲勞,尤其在併用白胺酸、異白胺酸或纈胺酸等支鏈胺 基酸]",可謂完全抑制。又,已知含有支鏈胺基酸之腦細 胞代谢改善組成物(參照專利文獻7)及抗痴呆藥(參照專 文獻8)。惟,該等對於支鏈胺基酸於低血糖症狀,尤其 是對促進腦細胞等細胞對於葡萄糖之攝取則未提及。 、含有支鏈胺基酸之製劑已知有服用量少量化、只含有 ^或/、、'下感良好之支鏈胺基酸作為有效成分之醫藥用珠 膠照專利文獻4),改善味道或飲食之感覺,而在顯 濁時可維持良好懸濁性之含有支鏈胺基酸、懸濁化劑及界 劑之醫藥用乾糖漿劑(參照專利文獻5)或以保存時 人保奎存安定性良好之支鏈胺基酸作為料^ ^ ^ 、惟,該等對於促進腦細胞内糖 貝之攝取或抑制低血糖症狀亦未記载。 [專利文獻1]特開2__26289號公報 318661 6 200800153 [專利文獻2]特開2GGG-2629G號公報 ·* [專利 Q Ί 馱3]國際公開第2〇〇2/〇34257號說明書 .L專利文獻4]特開2〇〇3—22133〇號公報 [專利文獻5]特開2003-221329號公報 [專利文獻6]特開2003-221327號公報 [專利文獻7]特開平2-172915號公報 ,[專利文獻8]特開平3-275631號公報 【發明内容】 ⑩[發明欲解決之課題] 卷月之目的係提供經由促進腦細胞内 而可抑制低血糖症狀之組成物。貝之攝取 [解決课題之方法] 本赉明人為了達成上述目的, 办 現,支鍵胺基酸、其藥理學上可接受之鹽或該 ::促:=::攝取之作"結果可抑制低血; 亦即,本發明係有關 ⑴以含有至少-種以上選自支鏈胺基酸、其藥理學上可去 叉之鹽及該等之衍支物之化合物作為有效成分為特徵之使 血糖症狀抑制用組成物、 ⑵以支鏈胺基酸為至少-種以上選自士_酸、卜白 =及L-異白胺酸之化合物為特徵之上述(1)記载之組成 (3)以至少含有L-異白胺酸為特徵之上述⑵記载之組成 318661 7 200800153 物、 U)以L-異白胺酸、L-白胺酸及L_織胺酸之含有比例換算 •莫耳比為1 : (0至3) : (0至2)為特徵之上述(3)記載之組 成物、 (5)以另含有糖質為特徵之上述(1)至(4)中任何一項記載 之組成物、 (6 )以糖貝為葡萄糖為特徵之上述(5)記載之組成物、 以低血糖症狀為交感神經刺激症狀及/或腦症狀為特 籲徵之上述⑴至⑻中任何—項記載之低血糖症狀抑制用組 )、3有至:>、種以上t自支鏈胺基酸、其藥理學上可接 受之鹽及該等之料物之化合物作為有效成分為特徵之腦 細胞内糖質攝取促進劑、 (9)以支鏈胺基酸為至少—種以上選自㈣㈣、卜白胺 酸及L-異白胺酸之化合物為特徵之上述⑻記載之腦細胞
内糖質攝取促進劑、 (HO以至少含有L-異白胺酸為特徵之上述(9)記载之 胞内糖質攝取促進劑、 、 ⑴)以L-異白胺酸、L_白胺酸及[_結員胺酸之含有比例換算 莫耳比為1 . (G至3) : 至2)為特徵之上述⑻記載之腦 細胞内糖質攝取促進劑、 (12) 以另含有糖質為特徵之上述⑻至(⑴中任何一項纪 載之腦細胞内糖質攝取促進劑、 (13) 以糖貝為㈣糖為特徵之上述(⑵記載之腦細胞内糖 318661 8 200800153 質攝取促進劑、 / (14)以注射劑或顆粒形態為其特徵之上述(1)至(7)中任何 .一項記載之組成物、 (15)以注射劑或顆粒形態為其特徵之上述(8)至(13)中任 何一項記载之腦細胞内糖質攝取促進劑、 α6)含有至少一種以上選自支鏈胺基酸、其藥理學上可接 产之鹽及該等之衍生物之化合物,且為抑制低血糖症狀或 促進腦細胞内糖質攝取之食品、 (17)該食品為凍膠之上述(16)記載之食品、 (J8)以對哺乳動物投予至少一種以上選自支鏈胺基酸、其 藥理予上可接叉之鹽及該等之衍生物之化合物為特徵之抑 制低血糖症狀之方法、 (19)以對哺乳動物投予至少一種以上選自支鏈胺基酸、i 藥理學上可接受之鹽及該等之衍生物之化合物為特徵之促 進腦細胞内糖質攝取之方法、 (2〇)為了製造抑制低血糖症狀之組成物,使用至少一種以 上選自支鏈胺基酸、其藥理學上可接受之鹽 物及 (21)為了製造腦細胞内糖質攝取之促進劑,使用至少一種 以上選自支鏈胺基酸、其藥理學上可接受之鹽及該等之衍 生物。 [發明之效果] 根據本發明,由於可促進腦細胞内攝取糖質,而可防 止腦細胞内糖質水平降低,其結果可抑制低血糖伴隨之症 318661 9 200800153 狀0 本毛明之低血糖症狀抑制用組成物或腦細胞内糖質攝 取促進劑,由於幾乎不會改變血中之血糖質,尤其對糖尿 病患者之治療不會造成影#,可有效地祕目胰島素注射 或抗糖尿病藥造成低血糖症狀之病患。 本务明之低血糖症狀抑制用組成物或腦細胞内糖質攝 取促進劑,可促進作為腦細胞能量之㈣糖之攝取,不僅 可抑制因上述低血糖為起因之症狀,亦可抑制即使血糖值 正常’但因腦㈣水平降㈣起之與低血糖症狀相同之症 【實施方式】 以下,對於本發明以含有至少―種以上選自支鍵胺基 酸、支鏈胺基酸之藥理學上可接受之鹽及支鏈胺基酸或其 樂理學上可接受之鹽之衍生物之化合物作為有效成分為特
徵之低血糖症狀抑觀組成物或腦細胞内糖f攝取促進劑 加以詳細說明。 本發明所使用之支鏈胺基酸通常只要能滿足曰本藥业 之規格者即可,並無特職制,支鏈絲酸包括卜胺基 酸、D-胺基酸、,_胺基酸、r胺基酸u基酸、天缺 胺基酸、合顏基酸等所錢錢,較料天^卜胺基酸 或α-胺基酸。本發明所使用之支鏈胺基酸較好者可列舉 L’胺酸、L-白胺基或卜異⑽酸。料支鏈胺基酸可為 使用蛋白酶等’將源自作物或動物之蛋白f水解而得者, 亦可為經由微生物《法產生者’亦可為經由對有機酸導 318661 10 200800153 入胺基而得之合成胺基酸等。 核明之支鏈胺基酸之藥理學上可接受之鹽只要是盘 即可’並無特別限制,可列舉例如鈉鹽或 卸鹽仏金屬鹽、㈣等驗土金屬鹽、鹽酸鹽等I機酸睡 或乙酸鹽等有機酸鮮,較好為鹽酸鹽。具體而言可列ς ::L’胺酸鹽酸鹽、L-白胺酸鹽酸鹽或L—異白胺酸鹽酸 鹽等。 〜本發明所使用之支鏈胺基酸或其藥理學上可接受之鹽 籲之衍生物並無特別限制’可列舉例如s旨體絲體等。該醋 體只要是甲酯、乙酉旨、丙酉旨或異丙酉旨等低級烧基西旨即可, 並無特別限制。該場合之低級烧基以碳數i至6之烧基較 m之酉旨體可具體列舉例> L_續胺酉复乙醋、[―白胺酸 ,乙酯異白胺酸乙醋等。又’該肽體只要是二肽或三肽 等低χΚ肽即可,並無特別限制,較佳之肽體可具體列舉例 異白胺醯基一L_白胺酸、^丙胺醯基白胺酸、^白 _胺自皿基L丙胺酸、甘胺醯基_L_白胺酸或[_丙胺醯基-[― f胺酸胺等。因此’構成低聚肽之支鏈胺基酸以外之胺基 酸可為任何一種,包括L-胺基酸、D-胺基酸、α-胺基酸、 石-胺基酸、7 -胺基酸、天然胺基酸、合成胺基酸等所有 胺基酸。 该等支鍵胺基酸、其藥理學上可接受之鹽或該等之衍 ^物可單獨或將2種以上混合使用,以至少含有L-異白胺 酉文、其鹽或其衍生物者較佳,特別以至少含有^異白胺酸 者更佳。 11 318661 200800153 本發明組成物中之支鏈胺基酸、其藥理學上可接受 •之鹽或該等之衍生物可單獨或將2種以上混合使用。將2 •種以上混合使用時之含有比例並無特別限制。具體而言, 使用支鏈胺基酸、其藥理學上可接受之鹽或該等之衍生 物,例如L-異白胺酸、L-白胺酸或L·-纈胺酸時,該等化合 物可單獨或將2種以上混合使用,該化合物之混合比例換 异莫耳比為L-異白胺酸:L-白胺酸:L-纈胺酸=約} ·· (〇 至3) : (〇至2),更好為約1 : (〇至2· 5) : (〇至丨· 5)。又, •例如使用L-異白胺酸、L-白胺酸或L-纈胺酸之鹽或其衍生 ,時,各各分別換算為L-異白胺酸、L-白胺酸或L-纈胺酸 時’以上述莫耳比之比例較佳。 本發明之低血糖症狀係指因血中葡萄糖之濃度降低而 f生之症狀。葡萄糖為所有細胞最重要之能源,尤其腦之 月匕里依存匍萄糖,而在肌肉或其他組織之機能之執行, 葡<萄糖亦不可欠缺,因此,血中葡萄糖之濃度若降低,則 _腦及肌肉或其他組織之機能之執行不佳,而產生症狀。該 症=並,特別限制’可列舉例如交感神經刺激症狀或腦症 狀,又感神經刺激症狀可列舉例如不安感、空腹、蹣跚、 暈無力、脫力感、倦怠、想打呵欠、焦燥、顫抖、悸 動顏面蒼白、心律過快、發汗或振戰等,腦症狀可列舉 f如頭痛、視力障礙、複視、眼晴模糊、集中力或計算力 ^退、健忘、嗜睡、意識障礙、痙攣、精神或身體異常行 動或昏睡等。 低血糖可列舉血糖值在約6〇mg/di以下之狀態,該血 318661 12 200800153 糖值亚未限疋。例如糖尿病等血糖較高的人經由注射姨島 ,素或服用降血糖劍使血糖值下降時,或即使是健康人,在 .空腹或急賴烈運動料至血糖值急速降時,血糖值雖然 在为lOOmg/cU ’亦會產生與低血糖症狀相同之症狀,該 等引起與低血糖症狀相同症狀之症狀等亦包含於本發明。 本發明之低血糖症狀抑制用組成物係指用於抑制或改 ,因血液中糖量成為低的狀態而引起之症狀之組成物。 —本發明之低血糖症狀抑制用組成物在陷入低也糖症時 虽然可以使用’在未成為低血糖症之狀態時亦可用於預防。 本發明之腦細胞内糖質攝取促進劑由於可促進腦細胞 内之糖質,尤其是作為腦内唯一能源之葡萄糖之攝取,而 可抑制腦内葡萄糖攝取受到抑制之症狀,例如抑制上述低 ::症狀或因某種理由’即使不是低血糖,但因腦内葡萄 糖水平降低而引起之與低血糖症狀相同之症狀等。 腦細胞内糖質攝取促進劑由於預測亦可促進腦以外之 細胞’例如肌肉細胞、神經細胞、其他細胞對糖質之攝取, 而期待可使上述肌肉細胞、神經細胞或其他細胞活化。 本發明之低血糖症狀抑制用組成物或腦細胞内糖質 ,促進劑以另含有糖質者較佳。該糖質並無特別限制,、較 好列舉例如核糖、去氧核糖、葡萄糖、果糖或半乳 糖類’麥芽糖、蔗糖或乳糖等雙糖類或直鏈澱粉、支㈣ ::糖原等多糖類等。糖質中又以單糖類更佳,以在生體 内立刻成為可利用之能源的葡萄糖最佳。 於該情況’糖質之含有比例並無特別限制,例如對於 318661 13 200800153 支鍵胺基酸1莫耳,換算為葡萄糖以約o. mo莫耳較佳。 ▲ 本發明之低血糖 、 .取促進劑可與製劑學制用組成物或腦細胞内糖質攝 與食品衛生法上核准之之添加物一起以醫藥形態或 隹之添加物一起以食品形態提供。 本發明之低血牆、片收^, 取促進劑作成醫举^ t制用組成物或腦細胞内糖質攝 用固形劑、内服用液 仅卞之内服 =肉内、腹腔内-射等)等使用。經口投予用:内:: 於内服用固形料可=%義劑、散劑或顆粒劑等。 制私人+ ^中可使用之添加劑可列舉例如賦形 Μ、黏合劑、崩解劑 ^ ^ 並無特別限制,可歹兴二 或濕潤劑。賦形劑 甘露糖醇等。黏4;:1Γ糖、乳糖、葡萄糖、殺粉或 羧甲μ%* γ 別限制,可列舉例如阿拉伯膠、 =彻酮(一done,亦即聚 :丨 亚無特別限制,可列舉例 予朋w 維素或低取代度幾丙基纖1二素、殿粉、結晶纖 可列舉例如滑石粉、硬:酸:4薄!,並無特別限制, 安宏挪、戸 更月曰齔鎂、硬脂酸鈣或二 女疋劑、濕潤劑並無特別限制, 7寺 桂酸鈉或丙三醇等 “Η如榉棣酸酐、月 以上合併你田劑可單獨使用,亦可將2種 典第14修正跋制内卞服用固形劍根據常法’例如根據曰本藥 酸、並越❹等:劑::記载之方法等’將例如支鏈胺基 呈體而顆與添加劑等混合、製劑化而獲得。 顆粒劑以例如於支鏈胺基酸、其鹽或該等之衍 318661 14 200800153 生物中加入上述賦形劑、黏合劑、崩解劑等,均句混合後 .以例如壓縮造粒、轉動造粒、喷霧乾燥造粒、擠壓造粒、 ,粉碎造粒、流動層造粒或攪拌造粒等作成粒狀較佳。又, 錠劑為例如於支鏈胺基酸、其鹽或該等之衍生物中加入上 述賦形劑、黏合劑、崩解劑等均勻混合,將所得之混合物 直接壓縮成型而製造或將支鏈胺基酸、其鹽或該等之:生 ,物與賦形劑、黏合劑、崩解劑等預先製造之顆粒以原狀或 加入上述添加劑均勻混和後,壓縮成型即可製造。顆粒劑 或錠劑係根據期望’可以適當之塗覆劑(明膠、白糖、阿拉 伯膠、巴西棕_等)或腸溶性塗覆劑(例如乙酸苯二甲酸 纖維素、甲基丙烯酸共聚物、羥丙基纖維素苯二甲酸醋、 羧甲基乙基纖維素等)等作成劑皮。又,膠囊劑為例如將於 支鏈胺基酸、其鹽或該等之衍生物中加入上述賦形劑、奔 H崩解劑等並均勾混合之混合物’根據期望作成粒狀 者或作成之粒狀物施以塗覆劑作為劑皮者,填充於膠囊 可製造。 内服用固形劑中之支鏈胺基酸、其鹽或該等之衍生物 之含有比例並無特別限制,惟支鏈胺基酸之合計量, 形製劑全體以約為1至90質量%較佳。 經口投予用之内服用液劑可列舉例如水劑、懸濁劑、 乳劑、糖漿劑或酏劑等。於該等液劑中可使用之添加劑可 列舉例如精製水、乙醇或該等之混合液等溶劑等。又 内服用液劑亦可含有懸濁化劑(例如阿拉伯膠、_菜、 基纖維素、經丙基纖維素等)、乳化劑(例如聚山梨酸^ 318661 15 200800153 80阿拉伯膠等)、矯味劑(例如單糖漿、蜂蜜、白糖、、酉 酉文荨)芳香劑(例如水揚酸曱酯、茴香油、柑橘油、薄 ,1醇(menthol)等)、保存劑(例如苯曱酸、苯曱酸鈉等): 緩衝劑(例如檸檬酸、碳酸氫鹽等)等。該等添加劑可單 使用,亦可2種以上合併使用。 於非經口投予用注射劑中可使用之添加劑可列舉例如 ,洛劑、安定劑、溶解補助劑、懸濁化劑、界面活性劑、乳 化劑、热痛化劑、緩衝劑或保存劑等。溶劑並無特別限制, 可列舉例如注射用蒸㈣、生理食鹽水、芝麻油等植物油,’ 乙醇、、異丙醇、丙二醇、丨,3_ 丁二醇或聚乙二醇等。安〜 =、溶解補助劑並無特別限制,可列舉例如谷胺酸、天= 月女酉夂,χκ山梨酸醋80 #。懸濁化劑並無特別限制,可列兴 例如緩甲基纖維素納或甲基纖維素等纖維素衍生物或西主 蓍膠或阿拉伯膠等天然膠類等。界面活性劑並無特別限汽 =,可列舉例如山梨糖醇酐脂肪酸醋、聚氧化乙烤山梨糖 醇酐脂肪酸醋、聚氧化乙烯脂肪酸醋、加氫訪油之聚氧 :匕乙_或㈣脂等。乳化劑並無特別限制,可列舉例如 1乳硬脂酸醋(poiyoxy! steme)、聚桂醇(_嶋⑽ f)、聚山梨酸賴或阿拉伯膠等。無痛化劑並無特別限 可列舉例如胺基苯㈣乙®旨、肌醇、鹽酸美普卡因 醢ePrylcain HCi)、鹽酸利多卡因⑽。如讀1)、氣丁 *摔檬酸或其鹽,糖、•或其 =或 保存劑並無特別限制’可列舉例如對經基苯,酸醋Γ氯化 318661 16 200800153 苯甲烷銨(benzaikonium chl〇rid :等。該等添加劑可單獨使用,亦^;上糖醇酐酸鹽 .注射劑係根據常法,例如經由併使用。 酸、其鹽或該等之衍生物盘予力心^作法將支鏈胺基 制、Α 物躲加劑等適當溶解等而。 錢之注射劑係填充於安瓶、小瓶、玻璃或聚乙二二 容器(包括袋狀)等,並加以滅菌 乙却衣輸液 袋狀)例如可盘脫氧气等一 触~衣輸液容器'(包括 '牡、 /、脫虱间以氣體阻障性外裝材料包 二=劑可製造成無菌固形劑’例如凍結乾燥品,在使 用:騎於無菌化或無菌注射用蒸麻或其他溶劑中使 別If二胺基酸、其鹽或該等之衍生物之含有比例並無特 S;:=如為輸液製劑時,對於注射劑全體,支鏈胺基 之己计置以約O.i至1〇w/v%左右較佳。 本發明之低金糖症狀抑制用組成物或腦細胞内糖質攝 取促進劑另可添加維生素(例如維生素A、、維生素Βι、β2、 =1、維生素C、維生素D、維生素£、終酸、泛酸、葉 月二生物素、維生素F、維生素P、維生素Q、維生素U、 s &肌醇對羥基苯甲酸等)或支鏈胺基酸以外之胺基酸 色,,、苯丙胺酸、曱硫胺酸、酥胺酸、纈胺酸、組胺酸、 胺酸、丙胺酸、脯胺酸、精胺酸、麩胺酸、絲胺酸 等營養素。 内/ C含有本每明之低血糖症狀抑制用組成物或腦細胞 徑糖質攝取促進劑之醫藥之投予量可視製劑形態、投予途 仫、病患年齡、體重、疾病之程度等任意決定,並無特別 318661 17 200800153 為1至lOOOmg,較好投 根據期望可適當增減。 限制,通常成人每】公斤每i曰約 予約1至50〇mg範圍之量較適當, 又可1日分數次投予。 摄取:ί::2血糖症狀抑制用組成物或腦細胞内糖質 之/ ^力彡㈣’係將至少―種支鏈胺基酸、 物,較好至少將卜異白胺酸與食品㈣ 或其他食品中使用之各種成分混合,製 仏人&⑽。製造之食品形態並無特別限制,可為例如 劑、膠囊劑、散劑、顆粒劑、内服用液劑、固體食品、孰 ί至^狀之+流動食品、膠狀食品、飲料等所有食品开 之具體例可列舉例如清涼飲料、果汁魏酸菌勒 料專飲料,;東膠、糖果、餅乾或小甜餅等。該食品之製缝 方法並無特別限制,可使用公知之方法。 人^ d、膠囊劑、散劑、顆粒劑或内服用液劑除了使用 食品衛生法上認可之添加物(例如經丙基甲基纖維素、結晶 馨,維素/酉石酸、甘露糖醇、糖精納、甜菊、二甲基聚石夕 巩烷、對羥基苯甲酸酯等)替代上述醫藥中之錠劑、膠囊 劑、散劑、顆粒劑或内服用液劑之添加物以外,可以同樣 之方法製造、使用。 7 製造飲料時,必要時可配合香料、著色料、天然果汁 果肉、乾酪或巧克力等風味物質或合成甜味料等添加物。 該添加物可單獨使用或2種以上組合使用。 製造乳狀至果醬狀之半流動食品、膠狀食品,,例如凍 膠%’除了上述飲料之成分外,以另添加1種或2種以上 318661 18 200800153 作為凝膠化劑之洋菜、日韓、卡拉膠(Carrageinan)、結冷 ‘ .(Gellangum)“占嘴膠、刺槐膠(1〇custbeangum)、果膠、 •褐藻酸納、褐藻酸卸或其他通常使用之增黏多糖類等較 佳。凝膠化劑之配合比例對於康膠1〇〇質量份約為2質量 份以下,較好約〇· 2至2質量份。 食品中之支鏈胺基酸、其鹽或該等之衍生物之含有比 '例並無特別限制,以支鏈胺基酸之合計量為約2至6〇質 %較佳。 • 此製造之食品可作為抑制低血糖症狀或促進腦細胞 、内糖質攝取之機能性食品使用。該等食品在其包裝等時較 好付有以作為抑制低血糖症狀或促進腦細胞内糖質攝取用 為宗旨之說明。 上述食品為成人(約60公斤)每日以攝取支鏈胺基酸、 其鹽或該等之衍生物約〇· 1至2〇g左右之量較佳。 [實施例] 馨以下,基於製劑例及試驗例對本發明作更詳細之說 明,但是本發明並不只限於該等者。 <製造例1 > 將L-異白胺酸300g溶解於注射用蒸餾水,以氕氧化 鈉將溶液之pH調整為6. 50後,再加入注射用蒸餾將 全量調整為10L。獲得之溶液以膜過濾器過濾,充填於聚 乙烯製輸液袋每袋各50OmL、密封,於105。〇進行古芦二貪 滅菌40分鐘,將其與脫氧劑(三菱氣體化學公司製造了虱 品名愛奇雷斯)一同’以聚乙烯醇多層膜製之氣體性: 318661 19 200800153 裝體包裝而獲得注射齊j。 . <製造例2> • 將^異白胺酸150§及L-纈胺酸150g溶解於注射用菽 餾水,以氫氧化鈉將溶液之邱調整為6. 5〇後,再加入裔 :用:館水’將全量調整為10L。獲得之溶液以膜濾二入過主 :慮:填1至聚乙烯製輸液袋各袋填充5〇〇mL、密封,於邮 /C進行高壓蒸氣滅菌40分鐘’與脫氧劑(三菱氣體化風八 司製造;商品名愛奇雷斯)一㈤,以聚乙烯醇多層膜製:: ⑩體阻障性外裝體包裝,獲得注射劑。 、 <製造何3> 將L-異白胺酸300g溶解於注射用蒸餾水,以气气化 納^容液之PH調整為6.5〇後’再加人注射用蒸麻,將 全量調整為1 0L,以膜濾器過濾。 、另一=面,將葡萄糖lOOOg溶解於注射用蒸餾水,加 入庄射用涤餾水將全量調整為i 0L,以膜濾器過濾。 • 將該等溶液以各5〇〇mL填充於聚乙烯製2室輸液袋之 各室 '密封,於105°C進行高壓蒸氣滅菌4〇分鐘,將^與 脫氧劑(三菱氣體化學公司製造;商品名愛奇雷斯)一同Γ 以聚乙烯醇多層膜製之氣體阻障性外裝體包裝,獲得注射 劑。 又 、 又,於使用時擠壓該注射劑2室中之j室或2室一起 擠壓,將2室連結,作成混液,作為注射液使用。 <製造例4> 將L-胺基丙醯基—L-白胺酸1〇〇〇g' L-異白胺酸3〇〇g 318661 20 200800153 及L_纈胺酸240g溶解於注射用蒸餾水,以氫氧化鈉將溶 、液之pH調整為6. 5 0後再加入注射用蒸镏水,將全量調整 ^為10L。獲得之溶液以膜濾器過濾,於聚乙烯製輸液袋中 每袋各填充該溶液500mL、密封,於105°C進行高壓蒸氣滅 菌40分鐘,將其與脫氧劑(三菱氣體化學公司製造;商品 名愛奇雷斯)一同,以聚乙烯醇多層膜製之氣體阻障性外裝 體包裝,獲得注射劑。 y <製造例5 > ⑩ 首先在精製水10L中加入每丙基曱基鐵維素120 g及結 晶纖維素·羧甲基纖維素鈉10g,分散之。接著,在該分 散液中加入酒石酸100g、甘露糖醇lOOOg、糖精鈉10g、 甜菊5g、二曱基聚矽氧烷40g、對羥基苯曱酸丙酯2g及對 羥基苯曱酸曱酯5g,使溶解。接著,加入L-異白胺酸950g、 L-白胺酸1900g、L-纈胺酸1150g,以均化器使懸濁,以氫 氧化鈉將溶液之pH調整為6. 5後再以均化器使均一懸濁, 調製懸濁液。 另一方面,將洋菜粉末40g加入精製水2L中,調製於 約80°C加溫溶解之物,於此處加入上述懸濁液6000g、鳳 梨香料40g,混合。獲得之混合液以各100g填充於容器、 密封後冷藏,調製凍膠。 <製造例6> 將L-異白胺酸50(^、[-白胺酸1000忌、纈胺酸600容、 檸檬酸酐1 OOg及羥丙基纖維素50g均一混合,添加蒸餾水 3 0 0 g並加以造粒。 21 318661 200800153 將造粒物於6 0 C乾煉2小時後通過24網目篩,獲得 〜顆粒。在鋁箔層壓棒狀袋(aluminiumlaminat bag)填充獲 •得之顆粒各4· 5g、密封,作為最終製品。 <試驗例1>經口投予支鏈胺基酸(以下稱為bcaa (Branched-Chain Amino Acid))促進腦中糖質攝取之作用 (1) 調製被驗液
、白胺酸群:將L-白胺酸3g加入生理食鹽水1〇〇11^中, /以均化器懸濁之L-白胺酸懸濁液作為白胺酸群之被驗液。 泰異白胺酸群:將L_異白胺酸3g加入生理食鹽水⑽mL 中’以均化器懸濁之L-異白胺酸懸濁液作為異白胺酸群之 被驗液。 (2) 試驗方法
將雄性6週齡Wistar老氣(日本查耳斯•利巴((:harie 只⑽)公司)在自由攝食精製飼料AIN_93G(曰本農產工業 (股)公司)及自由飲水下飼養14日後,在8週齡時以體售 :為3群(對照組、白胺酸群、異白胺酸群)。分成3利 在乙喊麻醉下將老鼠頸部切開,在頸靜脈内插人導管。a 管之另-端通過皮内於背部露出,經由導線連接並固定方 安全帶’將老鼠收容於個別代謝籠中,經由導管將生理J 鹽液以lmL/小時/個體之速度對老R持續注人。隔曰, 2照群老W/公斤體重之用量經口投予生理食 對白胺酸群及異白胺酸群老鼠以〇 45g/i5mL/公 =之用量各自經口投予被驗液,亦即L-白胺酸細 及異白'胺酸懸濁液。被铪、、右机t Μ 饭驗液投予後20分後’經由導管 318661 22 200800153 將2[1,2~11]-去氧葡萄糖(200(〕6〇15^111〇〇36))以30// • Ci/kg於約3秒鐘靜脈内投予。靜脈内投予後2、1{μ 2〇、 • 30及40分鐘,經由導管各自採血3〇〇// l,血液以肝素處 理後將血漿分離。分離之血漿供給2DG量及血糖值之測 定。將血漿20 // L放入液體閃爍計數器測定用之小瓶中, 於此加入閃燦劑(scinti 1 later)5mL,混合後以液體閃爍計 數器測定血漿中之氚量(計算),作為2DG量。又,血糖值 係經由葡萄糖氧化酶色素法測定。 • 投予被驗液1小時後,以約3秒對老鼠靜脈内注入戊 巴比妥鈉50mg/kg,,在麻醉下從腹部大動脈藉由肝素採 血進彳亍脫血。脫血後摘出腦組織’於該腦組織加入其重量 4倍量之1N氫氧化鈉,以水浴於60°C加熱1小時,使腦組 織溶解。在腦組織之溶解液中加入與上述1N氫氧化鈉同量 之1N鹽酸,中和,作為腦組織之中和均漿。 中和均漿中之2DG量:在400 /z L之0· 15N硫酸鋅溶液 馨中加入中和均漿400 # L,再加入400 /z L之0· 15N氫氧化 鋇溶液,混合。離心(6000rpm,20分鐘)後將上清液分離。 將分離之上清液900 /z L放入液體閃爍計數器測定用小瓶 中,於此加入閃爍劑5mL,混合後以液體閃爍計數器測定 氚量(計數量),作為2DG之量。 中和均漿中之2DG及2DG-6P(2-[1,2-3H]-去氧葡萄糖 -6-磷酸)之量:在400 // L之中和均漿中加入800 // L之6 重量%PCA(過氯酸),混合。離心(6000rpm,20分鐘)後將 上清液分離。將分離之上清液9 0 0 // L放入液體閃爍計數哭、 318661 23 200800153 測定用小瓶中,於其中加入閃爍劑1 OmL,混合後以液體閃 、爍計數器測定氚量(計數量),作為2DG及2DG-6P之量。 中和均漿中之2DG-6P量:從2DG及2DG-6P之量扣除 m 2DG量,算出2DG-6P量。將該2DG-6P量以血中2DG量及 血糖值修正,作為腦内糖質之攝取量。 統計處理係於分散分析後進行以對照群作為對照之 Dunnett’s多重比較之有意差檢定,以p<0. 05作為有意義 差。 — (3)試驗結果 結果示於第1圖。 根據結果,經口投予L-白胺酸懸濁液或L-異白胺酸懸 濁液,在投予被驗液1小時後腦細胞内糖質之攝取量與對 照群之該攝取量相比,顯示高值。可知尤其在異白胺酸群, 與對照群相比,有意義地促進腦細胞内糖質之攝取。 <試驗例2>經靜脈投予BCAA,對促進腦中糖質攝取之作 用 •⑴調製被驗液 對照群:以將葡萄糖溶解於精製水中使成為5質量% 之溶液作為對照群之被驗液。 混合胺基酸群:將葡萄糖溶解於精製水中使成為5質 量%之溶液,於其溶解阿米芭烈(商標登記:大塚製藥(股) 公司工廠製造)使成為1. 5質量%之溶液,以作為混合胺基 酸群之被驗液。 白胺酸群:將葡萄糖溶解於精製水中使成為5質量% 24 318661 200800153 之溶液’於其中溶解L-白胺酸使成為1.5質量%之溶液, ^以作為白胺酸群之被驗液。 . 異白胺酸群:將葡萄糖溶解於精製水中使成為5質量 %之溶液,於其中溶解L-異白胺酸使成為15質量 液’以作為異白胺酸群之被驗液。 纈胺酸群:將葡萄糖溶解於精製水中使成為5質量% 之溶液’於其中溶解纈胺酸使成為15質量%之溶液,以 作為續胺酸群之被驗液。 _ ( 2 )試驗方法 將雄性7週齡SD老氣(日本克雷)自由攝食精製飼料 AIN-93G(日本農產工業(股)公司)及自由飲水下飼養η曰 後’在8週齡時以體重分為5群(對照組、混合胺基酸群、 白胺酸群、異白胺酸群、類胺酸群)。分成5群後在乙鱗麻 醉下將老鼠之頸部切開,在頸靜脈内插入導管。導管之另 -端通過皮内於背部露出,經由導線連接並固定於安全 帶’將老鼠收容於個別代謝籠中。經由導管以侃/公斤 /小時之速度於對照群老鼠投予5質量%糖液,於混合胺 基酸群、白胺酸群' 異白胺酸群及㈣酸群老鼠則各自投 予被驗液。投予被驗液23小時後經由導管於約3秒鐘將 2-Π,2」Η]-去氧葡萄糖(2DG)以3〇,靜脈内投 予。靜脈内投予後2、10、2〇、3〇、4〇及6〇分經由導管各 自採企3 0 0 // L,金液以肝去忐田μ 從从肝素處理後將血漿分離。對分離之 血漿中之2DG量及血糖佶;隹γΑ 傲值進仃與試驗例1之試驗方法相同 之測定。 318661 25 200800153 戊巴=:,2二Γ氧葡萄.1蹲 〜戍巴比文鋼50mg/kg,以約3秒靜脈内投予, :腹部大動脈經由肝素採血進行脫 鮮下攸 版血後摘出腦組έ#, 於該腦組織中加入其重量4倍量 "、、且、哉
Rn°r ^ ^ 1 r ^ ^ 之1N虱軋化鈉,以水浴於 60C加熱1小使腦組織溶解。在腦組織之溶解液中加 入與上述1N氫氧化鈉同量之請醆 令士 4仏將a i t 意酉夂中和’作為腦組織 〜之中和均漿。中和均槳中之勝6P量以與試驗例i相同之 试驗方法測定,求得腦細胞内糖質之攝取量。 統計處理係於分散分析後,進行以對:群作為對昭之
DunneU’s多重比較之有意差檢定,以p<〇. 〇5作為有意義 差0 (3 )武驗結果 結果示於第2圖。根據結果,投予L_白胺酸、l_異白 月女酸、L-纈胺酸24小時後,腦細胞内糖質之攝取量與對照 群或混合胺基酸群相比,顯示高值,尤其在異白胺酸群及 绳胺酸群,與對照群相比’確認有促進腦細胞内糖質攝取 之傾向。 [產業上利用之可能性] 根據本發明,由於可促進腦細胞内糖質之攝取,可防 止腦細胞内糖質水平降低,其結果可抑制低血糖症狀,所 以’本發明可作為醫藥或機能性食品使用。又,本發明之 低ik糖症狀抑制用組成物或腦細胞内糖質攝取促進劑,由 於在幾乎不改變血中之糖量下可增加腦細胞内之糖量,尤 其可有效地使用於糖尿病患者等注射胰島素後之低血糠或 26 318661 200800153 投予抗糖尿病藥後之低血糖等 【圖式簡單說明】 第1圖示以對照群作為比較例,經σ L-異白胺酸1小時後老鼠腦細胞内糖二 '白胺酸或 中,縱轴表干?nr 取里之圖。圖 甲縱軸表不2DG-6P1,*表示對於對 口 (p<(K05)。 f马有思義差 各條柱之值以平均值(11=6)±標準誤差表示。 ' 第2圖示以對照群作為比較例,靜脈内投予混合胺基 必酸、L-白胺酸、L-異白胺酸或L-纈胺酸24小時後,老鼠 腦細胞内糖質攝取量之圖。圖中,緃軸表示2DG〜6p量。各 條柱之值以平均值(1^=4)±標準誤差表示。
318661 27
Claims (1)
- 200800153 十、申請專利範圍: "1 · 一種低血糖症狀抑制用組成物,其特徵為:含有至少一 • 種以上選自支鏈胺基酸、其藥理學上可接受之鹽及該等 之衍生物之化合物作為有效成分。 2.如申請專利範圍第丨項之組成物,其中,該支鏈胺基酸 係至少一種以上選自L-纈胺酸、L-白胺酸及l-異白胺 酸之化合物者。 一 3·如申叫專利範圍第2項之組成物,其中,該組成物係至 籲 少含有L-異白胺酸者。 4.如申請專利範圍第3項之組成物,其中,該L—異白胺 酸、L-白胺酸及卜纈胺酸之含有比例換算為莫耳比係 1 : (0 至 3) : (〇 至 2)者。 5·如申請專利範圍第!項至第4項中任一項之組成物,其 中,另含有糖質者。 / 6.如中請專利範圍第5項之組成物,其中,該糖質為葡萄 ^ 糖者。 •如申明專利範圍第丨項至第6項中任一項之組成物,其 中,該低血糖症狀為交感神經刺激症狀及/或腦症狀 者。 8·種腦細胞内糖質攝取促進劑,其特徵為:含有至少一 種以上廷自支鏈胺基酸、其藥理學上可接受之鹽及該等 之衍生物之化合物作為有效成分。 Q 女。^ I,上主 、 明專利範圍第8項之腦細胞内糖質攝取促進劑,其 中’該支鏈胺基酸係至少一種以上選自L-纈胺酸、 318661 28 200800153 白胺酸及L-異白胺酸之化合物者。 、10·如申請專利範圍第9項之腦細胞内糖質攝取促進劑,其 , 中,該促進劑至少含有L-異白胺酸者。 11 ·如申請專利範圍第1 〇項之腦細胞内糖質攝取促進劑, 其中’ L_異白胺酸、L-白胺酸及L-纈胺酸之含有比例 換算為莫耳比係1 : (〇至3) : (〇至2)者。 12·如申明專利範圍第8項至第11項中任一項之腦細胞内 ^ 糖質攝取促進劑,其中,另含有糖質者。 ΐί 13·如申請專利範圍第12項之腦細胞内糖質攝取促進劑, 其中,該糖'質為葡萄糖者。 14·如申請專利範圍第!項至第7項中任一項之組成物,其 t ’為注射劑或顆粒之形態者。 .如申請專利範圍第8項至第13項巾任—項之腦細胞内 糖質攝取促進劑,其中,為注射劑或顆粒之形態者。 16·種食品’其特徵為:含有至少一種以上選自支鍵胺基 _酸]其藥理學上可接受之鹽及該等之衍生物之化合物, 且係抑制低血糖症狀或促進腦細胞内糖質攝取者。 Π.,申請專利範圍第16項之食品,其中,該食品為束膠 18. -種低血糖症狀之抑制方法’其特徵為:對哺乳動物投 予至少一種以上選自支鏈胺基酸、其藥理學上可 鹽及該等之衍生物之化合物。 :種促進腦細胞内糖質攝取之方法,其特徵為:對哺乳 動物投予至少—種以上選自支鏈胺基酸、其藥理學上可 318661 29 19· 200800153 接受之鹽及該等之衍生物之化合物。 20. —種至少一種以上選自支鏈胺基酸、其藥理學上可接受 " 之鹽及該等之衍生物之用途,係用於製造抑制低血糖症 狀之組成物。 21. —種至少一種以上選自支鏈胺基酸、其藥理學上可接受 之鹽及該等之衍生物之用途,係用於製造腦細胞内糖質 攝取促進劑。30 318661
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005298089 | 2005-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200800153A true TW200800153A (en) | 2008-01-01 |
Family
ID=37942609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095137284A TW200800153A (en) | 2005-10-12 | 2006-10-11 | Composition for inhibiting low blood sugar syndrome |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100197787A1 (zh) |
EP (1) | EP1935417A4 (zh) |
JP (1) | JPWO2007043363A1 (zh) |
KR (1) | KR20080064834A (zh) |
CN (1) | CN101287458A (zh) |
TW (1) | TW200800153A (zh) |
WO (1) | WO2007043363A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI503128B (zh) * | 2007-07-31 | 2015-10-11 | Ajinomoto Kk | A granule preparation containing an amino acid with excellent taste |
EP2098124A1 (en) * | 2008-03-03 | 2009-09-09 | Nestec S.A. | Carbohydrate gel |
PL2098125T3 (pl) * | 2008-03-03 | 2012-02-29 | Nestec Sa | Zżelowany produkt spożywczy z wysoką skutecznością przyjmowania węglowodanów |
WO2012099082A1 (ja) * | 2011-01-17 | 2012-07-26 | 味の素株式会社 | 分岐鎖アミノ酸含有ゼリー |
GB201108343D0 (en) | 2011-05-18 | 2011-06-29 | Hibernation Honey Ltd | Honey composition |
KR101352422B1 (ko) * | 2011-11-23 | 2014-01-20 | 주식회사 아리바이오 | 저혈당 개선용 조성물 |
CN102908337B (zh) * | 2012-10-12 | 2014-03-05 | 大连医诺生物有限公司 | 微囊化氨基酸组合物及其制备方法 |
JP5854077B2 (ja) * | 2014-04-14 | 2016-02-09 | 味の素株式会社 | 経口摂取用ゲル状組成物、及びその製造方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003870A1 (en) | 1984-03-01 | 1985-09-12 | Vernon Erk | A method of treating hypoglycemia in vertebrates |
AU599567B2 (en) | 1984-03-01 | 1990-07-26 | Vernon Erk | Method of treating memory disorders of the elderly |
JPH02172915A (ja) | 1988-12-23 | 1990-07-04 | Ajinomoto Co Inc | 脳細胞代謝改善組成物 |
JPH03275631A (ja) | 1990-03-19 | 1991-12-06 | Ajinomoto Co Inc | 抗痴呆薬 |
JP3341769B1 (ja) | 2002-01-25 | 2002-11-05 | 味の素株式会社 | 分岐鎖アミノ酸含有チュアブル剤 |
JP3341770B1 (ja) | 2002-01-30 | 2002-11-05 | 味の素株式会社 | 分岐鎖アミノ酸を含有するゼリー剤 |
JP4281281B2 (ja) | 2002-01-30 | 2009-06-17 | 味の素株式会社 | 分岐鎖アミノ酸を含有するドライシロップ剤 |
EP1591116A4 (en) | 2003-02-06 | 2008-05-28 | Otsuka Pharma Co Ltd | INHIBITOR OF INCREASE IN PERIOPERATIVE GLYCEMIC RATE |
-
2006
- 2006-09-29 EP EP06798483A patent/EP1935417A4/en not_active Withdrawn
- 2006-09-29 JP JP2007539871A patent/JPWO2007043363A1/ja active Pending
- 2006-09-29 WO PCT/JP2006/319574 patent/WO2007043363A1/ja active Application Filing
- 2006-09-29 US US11/992,489 patent/US20100197787A1/en not_active Abandoned
- 2006-09-29 KR KR1020087008710A patent/KR20080064834A/ko not_active Application Discontinuation
- 2006-09-29 CN CNA2006800379079A patent/CN101287458A/zh active Pending
- 2006-10-11 TW TW095137284A patent/TW200800153A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20080064834A (ko) | 2008-07-09 |
EP1935417A4 (en) | 2009-06-10 |
JPWO2007043363A1 (ja) | 2009-04-16 |
US20100197787A1 (en) | 2010-08-05 |
CN101287458A (zh) | 2008-10-15 |
EP1935417A1 (en) | 2008-06-25 |
WO2007043363A1 (ja) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7932288B2 (en) | Composition for relieving subjective symptoms of fatigue | |
TW200800153A (en) | Composition for inhibiting low blood sugar syndrome | |
JP6345243B2 (ja) | 円武扇発酵物含有食品または飲料組成物 | |
KR102485261B1 (ko) | 필러의 효능 유지용 조성물 | |
KR102295696B1 (ko) | 피로회복을 위한 경구용 수액분말 조성물 및 이의 제조방법 | |
JP2014015430A (ja) | 深部体温上昇剤 | |
JP4280310B2 (ja) | アミノ酸組成剤 | |
JP2019182881A (ja) | 末梢神経障害の予防又は改善用組成物 | |
WO2014010656A1 (ja) | 優れた血中アルコール濃度低下促進剤 | |
JPWO2006001344A1 (ja) | イソソルビド含有ゼリー製剤 | |
JP5266058B2 (ja) | 抗うつ剤 | |
JP2008266291A (ja) | フコイダンを有効成分とする酸性尿改善飲食物および経口投与用医薬組成物 | |
WO2014010658A1 (ja) | ヒハツ配合製剤 | |
JP2006193435A (ja) | 疲労改善剤 | |
CN114569686B (zh) | 一种解酒组合物、具有解酒功效的片剂及其制备方法 | |
KR20200140103A (ko) | 틱장애, 뚜렛증후군 또는 강박장애의 예방 또는 치료용 조성물 | |
KR20010009653A (ko) | 성기능 장애를 위한 치료용 조성물 | |
CN114617916B (zh) | 一种枇杷叶提取物及其在康养方面中的应用 | |
KR101458670B1 (ko) | 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법 | |
KR20010019397A (ko) | 발기부전 치료용 조성물 | |
JP2010265186A (ja) | 貧血予防用組成物 | |
JPH11171763A (ja) | 肝疾患治療剤 | |
KR20230077096A (ko) | 수면의 질을 향상시킬 수 있는 기능성 건강식품 조성물 | |
JP5795562B2 (ja) | 食欲抑制剤 | |
JP2024017059A (ja) | 感冒症状抑制剤 |